Habbel Victoria Susanne Antonia, Mahler Elisa Annabelle, Feyerabend Bernd, Oldhafer Karl-Jürgen, Lipp Michael Josef
Asklepios Campus Hamburg, Medizinische Fakultät der Semmelweis Universität, Hamburg, Germany.
Klinik für Allgemein- und Viszeralchirurgie, chirurgische Onkologie, Asklepios Klinik Barmbek, Hamburg, Germany.
Z Gastroenterol. 2020 Feb;58(2):146-151. doi: 10.1055/a-1083-6962. Epub 2020 Feb 12.
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare diagnosis, found more frequently in men than in women. Symptoms are unspecific abdominal disorders making that diagnosis difficult to set. Causes of DMPM are yet to be discovered in entirety. Asbestos exposure is the reason for approximately 7 % of all peritoneal mesotheliomas. Until the evaluation of systematic cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) DMPM was a fatal diagnosis with a median overall survival (OS) of 4-13 months. The prognosis of DMPM dramatically improved with implementation of CRS and HIPEC to an OS of 30-92 month nowadys. CRS and HIPEC were performed in this case.
弥漫性恶性腹膜间皮瘤（DMPM）是一种罕见的诊断疾病，男性比女性更常发病。症状为非特异性腹部疾病，这使得诊断困难。DMPM的病因尚未完全明确。石棉暴露是所有腹膜间皮瘤约7%的病因。在系统细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）得到评估之前，DMPM是一种致命诊断，中位总生存期（OS）为4至13个月。随着CRS和HIPEC的实施，DMPM的预后显著改善，目前OS为30至92个月。本病例进行了CRS和HIPEC。
